Novo Nordisk presents new post hoc analyses from phase 3 REDEFINE 1 trial

At ObesityWeek, Novo Nordisk (NVO) presented new post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular risk factors, including hypertension and systemic inflammation. The results from the post hoc analysis of REDEFINE 1, exploring the CV risk reduction potential of investigational CagriSema, were also simultaneously published in Hypertension. With CagriSema treatment, systolic blood pressure was reduced by -10.9 mmHg over 68 weeks, versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo. This reduction was seen regardless of BMI. In the CagriSema group, nearly 4 out of 10 people who had been on blood pressure-lowering medication were able to cut down or stop this medication during the trial. “We’re very excited by the results of these analyses of CagriSema, which show promising results of combining cagrilintide with the proven significant effects of semaglutide on CV health,” said Martin Holst Lange, chief scientific officer and executive vice president of Research & Development at Novo Nordisk. “People living with obesity have treatment goals that often include both losing weight and improving overall health. That’s why we continue to explore new therapies that we hope will deliver on weight loss needs while reducing the risk of obesity-related health issues like cardiovascular disease.”